Clinical Trial Update: Reparixin in Prevention of Delayed Graft Function After Kidney Transplantation [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on reparixin to prevent delayed graft function after kidney transplantation following ischemia-reperfusion injury.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ischemia-reperfusion Injury
• Kidney Diseases

Drugs mentioned

• Reparixin (reparixin)

Snippet

Sponsor: Dompé Farmaceutici S.p.A | Conditions: Ischemia-Reperfusion Injury, Kidney Diseases | Phase 2 | Status: COMPLETED | Results posted: 2020-04-14